 |
|
Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
Chang Hyun Park, Mee Kum Kim, Eun Chul Kim, Jae Yong Kim, Tae-Im Kim, Hong Kyun Kim, Jong Suk Song, Kyung-Chul Yoon, Do Hyung Lee, Hyung Keun Lee, Tae-Young Chung, Chul Young Choi, Hyun Seung Kim
Korean J Ophthalmol. 2019;33(4):343-352. Published online 2019 Aug 5 DOI: https://doi.org/10.3341/kjo.2018.0116
|
|
Citations to this article as recorded by
 Management of inflammation in dry eye disease: Recommendations from a European panel of experts
Elisabeth M Messmer, Sajjad Ahmad, José M Benitez del Castillo, Ewa Mrukwa-Kominek, Maurizio Rolando, Oksana Vitovska, Christophe Baudouin
European Journal of Ophthalmology.2023; 33(3): 1294. CrossRef Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems
Garima Rawat, Shital Kolhe, Dhwani Rana, Sagar Salave, Derajram Benival
Critical Reviews™ in Therapeutic Drug Carrier Systems.2023; 40(5): 1. CrossRef Update on Dry Eye Disease Treatment: Evidence From Randomized Controlled Trials
Omur O. Ucakhan, Tuna Celik-Buyuktepe, Lin Yang, Brian Wogu, Penny A. Asbell
Eye & Contact Lens: Science & Clinical Practice.2023; 49(12): 542. CrossRef Meibomian gland atrophy with duration of Sjogren’s syndrome in adult females
Sung Rae Noh, Jae Lim Chung, Jeong Min Lee, Kyoung Yul Seo, Kyungmin Koh
International Ophthalmology.2022; 42(1): 191. CrossRef A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
Hugo Quiroz-Mercado, Everardo Hernandez-Quintela, Kuei Hsun Chiu, Eugenia Henry, Jeffrey A. Nau
The Ocular Surface.2022; 24: 15. CrossRef Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update
Mehrdad Afarid, Shirin Mahmoodi, Roghayyeh Baghban
Journal of Nanobiotechnology.2022;[Epub] CrossRef Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis
Dongyang Gao, Zhuoli Da, Kan Yang, Yuanyuan Shi
Frontiers in Pharmacology.2022;[Epub] CrossRef Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease
Youngsub Eom, Jong Suk Song, Hyo Myung Kim
Journal of Ocular Pharmacology and Therapeutics.2022; 38(10): 682. CrossRef Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome
Mehmet Ozgur Cubuk, Ahmet Yucel Ucgul, Armagan Ozgur, Kemal Ozulken, Erdem Yuksel
International Ophthalmology.2021; 41(4): 1479. CrossRef Methods of drug therapy for severe dry eye disease
G. R. Semak
Proceedings of the National Academy of Sciences of Belarus, Medical series.2021; 18(1): 109. CrossRef The Protective Effect of an Eye Wash Solution on the Ocular Surface Damage Induced by Airborne Carbon Black Exposure
Xiangzhe Li, Boram Kang, Youngsub Eom, Hyung Keun Lee, Hyo Myung Kim, Jong Suk Song
Cornea.2020; 39(8): 1040. CrossRef Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
Chang Hyun Park, Hyung Keun Lee, Mee Kum Kim, Eun Chul Kim, Jae Yong Kim, Tae-im Kim, Hong Kyun Kim, Jong Suk Song, Kyung Chul Yoon, Do Hyung Lee, Tae-Young Chung, Chul Young Choi, Hyun Seung Kim
BMC Ophthalmology.2020;[Epub] CrossRef
|